Bayer earnings preview: Recent focus on asundexian momentum ahead of Q4 results Mar 3, 2026 06:00PM
Bayer reports phase I results for prostate cancer therapy Feb 27, 2026 12:48PM
Bayer's XOFIGO plus enzalutamide reduces death risk by 24% in prostate cancer Feb 26, 2026 11:28AM
Bayer proposes $10.5 billion to settle Roundup cancer lawsuits - Bloomberg Feb 17, 2026 10:20AM
Bayer's asundexian reduces stroke risk by 26% in phase III trial Feb 5, 2026 12:15PM


Jan 20, 2026 09:36AM Bayer AG (BAYN:GR) (BAYRY) PT Raised to EUR40 at BMO Capital
Jan 19, 2026 12:04PM Bayer AG (BAYN:GR) (BAYRY) PT Raised to EUR55 at BofA Securities
Jan 19, 2026 04:33AM Bayer AG (BAYN:GR) (BAYRY) PT Raised to EUR55 at Morgan Stanley
Dec 3, 2025 07:54AM Bayer AG (BAYN:GR) (BAYRY) PT Raised at BMO Capital as 'Positive SCOTUS Outcome Probability Improves '
Dec 3, 2025 02:57AM Morgan Stanley Upgrades Bayer AG (BAYN:GR) (BAYRY) to Overweight
Aug 7, 2025 03:05AM Bayer AG (BAYN:GR) (BAYRY) PT Raised to EUR35 at Goldman Sachs
Jun 11, 2025 05:57AM Kepler Cheuvreux Upgrades Bayer AG (BAYN:GR) (BAYRY) to Buy
Jun 5, 2025 01:58AM Goldman Sachs Upgrades Bayer AG (BAYN:GR) (BAYRY) to Buy
May 19, 2025 11:29AM Bayer AG (BAYGN) announces FDA approval for Jivi
May 2, 2025 02:22AM BofA Securities Upgrades Bayer AG (BAYN:GR) (BAYRY) to Buy
Nov 19, 2024 02:47PM Bayer AG (BAYN:GR) (BAYRY) PT Lowered to EUR25 at CFRA
Nov 13, 2024 08:23AM Bayer AG (BAYN:GR) (BAYRY) PT Lowered to EUR26 at BMO Capital
Sep 6, 2024 02:36AM BofA Securities Upgrades Bayer AG (BAYN:GR) (BAYRY) to Neutral